# Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse

> **NCT01376167** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 851 (actual)

## Conditions studied

- Malaria, Vivax

## Interventions

- **DRUG:** Chloroquine 600mg
- **DRUG:** Chloroquine 300mg
- **DRUG:** Tafenoquine 50mg
- **DRUG:** Tafenoquine 100mg
- **DRUG:** Tafenoquine 300mg
- **DRUG:** Tafenoquine 600mg
- **DRUG:** Primaquine 15mg
- **DRUG:** Chloroquine 600mg (Part 2 )
- **DRUG:** Chloroquine 300mg (Part 2 )
- **DRUG:** Tafenoquine 300mg (Part 2)
- **DRUG:** Primaquine 15mg (Part2 )

## Key facts

- **NCT ID:** NCT01376167
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-24
- **Primary completion:** 2016-11-18
- **Final completion:** 2016-11-18
- **Target enrollment:** 851 (ACTUAL)
- **Last updated:** 2018-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01376167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01376167, "Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01376167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*